Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
58.1M
-
Shares change
-
+49.1M
-
Total reported value, excl. options
-
$909M
-
Value change
-
+$768M
-
Number of buys
-
41
-
Price
-
$15.64
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q4 2017
44 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q4 2017.
Denali Therapeutics Inc. - Common Stock (DNLI) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.1M shares
of 145M outstanding shares and own 40.03% of the company stock.
Largest 10 shareholders include Crestline Management, LP (20.6M shares), FMR LLC (9.34M shares), Flagship Pioneering Inc. (8.92M shares), BAILLIE GIFFORD & CO (4.92M shares), Temasek Holdings (Private) Ltd (4.41M shares), FIL Ltd (4.18M shares), Vanguard Group Inc (927K shares), NORGES BANK (650K shares), Alphabet Inc. (567K shares), and Mitsubishi UFJ Trust & Banking Corp (542K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.